Professor Ryan talking about psoriasis at the European Academy of Dermatology and Venereology Annual

Discussing the impact of psoriasis on the quality of life of patients and presenting the results of a global, phase 3b global study on effect of ixekizumab (Taltz), an anti-IL17A inhibitor, on genital psoriasis